Angiotensin receptor-neprilysin inhibitors improve the outcome of lung cancer patients with hypertension undergoing immune checkpoint inhibitors treatment

The use of ARNIs seemed associated with a lower all-cause mortality rate yet similar rate of cardiac events in lung cancer patients with hypertension and treated with ICIs. The findings of this single-center retrospective study warrant validation in larger prospective studies.